Patient-reported outcomes worse for patients with rheumatoid arthritis discontinuing TNF inhibitor

by Elana Gotkine

edited by Sadie Harley, reviewed by Andrew Zinin

Sadie Harley

Scientific Editor

Meet our editorial team
Behind our editorial process

Andrew Zinin

Chief Editor

Meet our editorial team
Behind our editorial process Editors' notes

This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

fact-checked

peer-reviewed publication

reputable news agency

proofread

The GIST Add to Preferred Sources

For patients with rheumatoid arthritis (RA), patient-reported outcomes (PROs) generally worsen shortly after tumor necrosis factor inhibitor (TNFi) discontinuation, according to a study published in the Journal of Rheumatology.

Michael M. Ward, M.D., M.P.H., from the National Institutes of Health in Bethesda, Maryland, and colleagues compared PROs over 48 weeks in a randomized, double-blind trial involving patients with RA in sustained remission/low disease activity treated with TNFi. Participants were randomly assigned to placebo (discontinuation of TNFi; 69 patients) or continuation of TNFi (33 patients).

The researchers found that group mean scores on the patient global assessment, pain score, and Health Assessment Questionnaire-Disability Index were significantly higher in the placebo than the TNFi group during the trial. Small or moderate effect sizes were seen for all PROs.

All measures were significantly higher in the placebo group at week 12 compared with week 0, but not at later times, corresponding with the timing of most relapses. The domains most affected were Short Form-36 bodily pain and social function. By trial end, after resuming TNFi treatment, PROs returned to baseline values.

"Patients who discontinued TNFi were more likely than those who continued TNFi to have worsening of several aspects of self-rated health. However, worsening tended to occur early after TNFi discontinuation, was generally moderate in severity, and was temporary, with most measures returning to baseline by trial end," the authors write. "These findings will help inform patients and aid decision-making among those considering TNFi de-escalation."

Publication details

Michael M. Ward et al., Patient-Reported Outcomes Following Discontinuation of Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis Remission/Low Disease Activity: A Randomized Placebo-Controlled Trial, The Journal of Rheumatology (2026). DOI: 10.3899/jrheum.2026-0356

Journal information: Journal of Rheumatology.

Key medical concepts

Rheumatoid ArthritisOutcome, Patient ReportedTumor Necrosis Factor Inhibitors

Clinical categories

RheumatologyClinical pharmacology Who's behind this story?

Sadie Harley

BSc Life Sciences & Ecology. Microbiology lab background with pharmaceutical news experience in oil, gas, and renewable industries. Full profile →

Andrew Zinin

Master's in physics with research experience. Long-time science news enthusiast. Plays key role in Science X's editorial success. Full profile →

Copyright © 2026 HealthDay. All rights reserved.

Citation: Patient-reported outcomes worse for patients with rheumatoid arthritis discontinuing TNF inhibitor (2026, October 26) retrieved 26 October 2026 from https://medicalxpress.com/news/2026-10-patient-outcomes-worse-patients-rheumatoid.html This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.